There has been slow progress in the development of new therapeutic strategies for treating brain tumours, partly because assessment of treatment response is difficult and largely reliant on simple bi-dimensional measurements of MRI contrast-enhancing regions. Hence, there is a clinical need to develop improved imaging techniques for monitoring treatment response. In this study, we evaluate VERDICT (Vascular, Extracellular and Restricted Diffusion for Cytometry in Tumors) MRI in mouse glioblastomas for the quantification of tumour microstructure and assessment of response to Temozolomide (TMZ) chemotherapy, and, we investigate the feasibility of applying VERDICT MRI in a range of human gliomas.
Quantitation of brain tumour microstructure response to Temozolomide therapy using non-invasive VERDICT MRI
Tom
INTRODUCTION
Gliomas are the most common type of primary brain tumour in adults with an annual incidence of 4-5/100,000 people. For newly diagnosed glioblastoma (GBM), the most common and malignant of the gliomas, no treatment has yet been shown to be more effective than maximal safe surgical resection followed by chemoradiation and adjuvant chemotherapy with Temozolomide (TMZ) (1) . There has been only a modest improvement in outcome over the last 10 years with three year survival increasing from about 4% in 1999-2000 to 10% in 2009-2010 (2) .
Despite new therapeutic strategies inhibiting angiogenesis and more recently immunotherapy (3), progress has been limited by the inherent difficulties in assessing treatment response in clinical trials. Traditional imaging of response utilizes measurements of enhancing tumour on T1-weighted MRI (4) and these have been confounded by the phenomena of pseudoprogession, whereby an increase in tumour volume, oedema and enhancement, shortly after completion of chemoradiation treatment is indistinguishable from progressive tumour (5, 6) and pseudoresponse, whereby a dramatic reduction in tumour enhancement following treatment with anti-angiogenic agents is thought to be due to vascular normalization rather than a true anti-tumour effect (7, 8) .
Although the current most widely used response assessment criteria for high-grade gliomas known as the RANO criteria (Response Assessment in Neuro-oncology) corrects for a number of these complexities (9) , there is still reliance on bi-dimensional measurements for contrast enhancing tumours. As enhancement in high grade gliomas reflects only one aspect of the biology of these tumours, i.e. blood brain barrier breakdown (10) , there is an urgent need to develop quantitative and robust imaging technologies to better assess tumour burden and response to treatment.
Diffusion weighted imaging (DWI), which is the technology that underpins VERDICT, has been widely shown to offer additional utility in brain tumours beyond tumour volume imaging (11) . DWI is sensitive to the restriction of water diffusion by tissue microstructure, and can therefore be used to probe structures below the resolution of the image acquisition. It does not require the administration of a contrast agent and does not require additional specialist equipment. The apparent diffusion coefficient (ADC) in gliomas has been shown to inversely correlate with tumour cell density (12, 13) , likely to be due to restriction of water motion in tightly packed cells, making DWI a technique of great interest for both grading and detecting disease recurrence (14) and for differentiating pseudoprogression from progressive disease (15, 16) .
DWI data are usually quantified by fitting a single exponential function to images acquired with increasing diffusion weighting, to estimate the ADC (17) . More sophisticated models have been proposed, which include, but are not limited to: intravoxel incoherent motion (IVIM) (18) , diffusion tensor imaging (DTI) (19) , diffusion kurtosis imaging (20) and neurite orientation dispersion and density imaging (NODDI) (21) .
More recently, VERDICT has shown promise for non-invasively quantifying microstructural changes in tumours. To date, its use has been investigated in colorectal cancer (22) and prostate cancer (23) , and has shown a good ability to distinguish tumour from healthy tissue and to accurately quantify cell size and density. VERDICT utilises multiple MRI diffusion gradients to probe the microscopic motion of water molecules tumours at a range of length scales, and a three-compartment biophysical model is fitted to the DWI signal, providing estimates of intracellular volume fraction (fic), extracellular-extravascular volume fraction (fees), intravascular volume fraction (fv) and cell radius ( Figure S1 ). These parameters are particularly relevant to cancer, where cell proliferation is elevated and angiogenesis is a key factor in tumour progression.
To date, the ability of VERDICT MRI to evaluate brain tumours has not been investigated. In this study, we have investigated the use of VERDICT in a GL261 GBM mouse model (24) to assess pre-therapy microstructure and to measure response to Temozolomide therapy. We have then applied the optimised VERDICT model to a cohort of human adult gliomas in an initial feasibility study. Our hypothesis was that VERDICT MRI could detect tumour microstructural changes in response to therapy before macroscopic changes, with potential as a therapeutic marker in human glioma treatment trials.
MATERIALS AND METHODS

Mice and glioma cell implantation
All in vivo experiments were performed in accordance with the UK Home Office Animals Scientific Procedures Act, 1986 and United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines (25) .
Female, 8-weeks old, C57BL/6 mice were injected with 2x10 4 GL261 mouse glioma cells.
Mice were anesthetized with 4% isoflurane in an induction box and then transferred to a stereotactic frame (David Kopf Instrument, Tujunga, CA), where anaesthesia was delivered through a nose cone and maintained at 2%. The head was sterilised with 4% chlorhexidine and the skin was cut with a sterile scalpel to expose the skull. Coordinates were taken using a blunt syringe (Hamilton, 75N, 26s/2"/3, 5 μL): 2mm right and 1mm anterior to the bregma, corresponding to the right caudate nucleus. A burr hole was made using a 25-gauge needle.
The Hamilton syringe was lowered 4mm below the dura surface and then retracted by 1mm
to form a small reservoir. 2x10 4 GL261 cells were injected in a volume of 2 μL over two minutes. After leaving the needle in place for 2 minutes, it was retracted at 1 mm/min. The burr hole was closed with bone wax (Aesculap, Braun) and the scalp wound was closed using Vicryl Ethicon 6/0 suture.
Study design and administration of Temozolomide
Mice were implanted with glioma cells for imaging. At 13-days post inoculation (day 0), mice were randomly assigned to control or TMZ-treated groups (n = 12 for each), and baseline imaging was carried out. Immediately after scanning, and following recovery from anaesthesia, mice in the TMZ group were administered with a first dose of Temozolomide (Temodar, MerckKenilworth, NJ) by oral gavage (130 mg/kg in vegetable oil). Two further doses were given on consecutive days, to a total dose of 490 mg/kg. Mice in the control group received sham doses of vegetable oil according to an equivalent regimen. MRI was carried out every three days, to a final timepoint at 22-days post tumour injection (day 9).
MRI acquisition
Mouse MRI measurements were performed on a 9.4T horizontal bore scanner (Agilent Technologies, Santa Clara, CA) with a 205/120/HD 600 mT/m gradient insert. RF transmission was performed with a 72 mm inner diameter volume coil and a 2-channel receiver coil (RAPID biomed, Ripmar, Germany). Mice were anaesthetised with 1.5-2.0%
isoflurane in 2 l/min oxygen, and positioned prone in a cradle for imaging. The head was positioned within an MR-compatible head-holder and secured with plastic ear bars to minimise motion artefacts. Body temperature was maintained at physiological temperature using a hot water system and monitored using a rectal probe (SA Instruments, Stony Brook, NY). Respiration was monitored using a neonatal apnoea pad taped to the abdomen of the animal. An intraperitoneal infusion line was used for administration of gadolinium contrast agent (Magnevist, Bayer, Leverkusen, Germany).
Imaging Protocol
Following shimming, tumours were localised using a structural T2-weighted spin-echo sequence. For VERDICT, diffusion-weighted images were acquired in a coronal orientation using a 3-shot spin-echo echo planar imaging (EPI) sequence, which included the following parameters: TR = 3s, TE = min, data matrix = 64x64, FOV = 20x20mm, shots = 3, slice thickness = 0.5mm, slices = 5, averages = 2. In total, 46 diffusion weightings (each of 3 directions) were acquired in addition to a 42 direction DTI acquisition (b = 1000 s/mm 2 ).
Specific gradient combinations are detailed in 
Quantification of DWI data
VERDICT models the water signal from three non-interacting tissue compartments (22) . In brief, a BallSphereStick model ( Figure S1 ) characterises the diffusion signal, in which Ssphere is the signal from restricted water (intracellular), Sstick is the signal from blood (intravascular)
and Sball is the signal from the extracellular-extravascular space. The total signal within a voxel is the weighted sum of the contributions from each compartment, according to:
Further details on the functional form for each component can be found in Panagiotaki et al (22) .
Model-fitting was carried out in MATLAB (Mathworks, USA) using the open-source Camino toolbox (26) . In total, four parameters were estimated in this study: fic, fees, R (cell radius) and dv (intravascular diffusivity). For model stability, the intracellular and extracellularextravascular diffusivities were fixed: dic = 1x10 -9 , dees = 2x10 -9 m 2 /s respectively. The intravascular volume fraction was not fitted and instead was calculated as = 1 − ( + ).
Whole-brain ADC and VERDICT parameter maps were generated for visualisation, however, as the VERDICT model is an unsuitable descriptor of normal brain tissue, only parameter values within tumour ROIs were used in further analysis. In glioblastoma patients, ROIs were drawn around three separate regions corresponding to the tumour core, tumour rim and peritumoural zone. Analyses were performed independently on each of these regions.
Optical Projection Tomography
Optical projection tomography (OPT) of complete brains was used to quantify the blood volume of tumour tissue, in a subset of mice (n = 1 control, n = 1 TMZ-treated), for comparison with in vivo MRI data. The full method for fluorescently-labelling the vasculature, clearing the mouse brains, imaging, and image processing is detailed in the Supplementary Material.
Histology
Intracellular volume fraction was quantified from histology for comparison with VERDICT MRI using an in-house MATLAB script. After the final MRI scan, mouse brains were extracted (n = 8 control, n = 6 TMZ-treated), immersion fixed in 4% PFA, and then sliced in a coronal orientation and stained with hematoxylin and eosin (H&E). A k-means threshold was applied to the H&E slices to estimate the ratio of the stained brain tumour cells to unstained extracellular-extravascular space, for comparison with the VERDICT fic parameter.
Patients and MRI acquisition
The human MRI component of the study was performed with local ethics committee approval and patients provided written informed consent. Nine untreated patients with brain tumours Table 2 . Total acquisition time was 12 minutes. DWIs were normalised to b = 0 s/mm 2 (B0) images acquired with the same TE.
Five patients immediately underwent a second set of same-session scans for assessment of repeatability. Prior to VERDICT analysis, diffusion images were registered and corrected for eddy current effects using the ECMOCO toolbox (27) in SPM (28) . Tumour masks were created by manual segmentation of B0 images. For the GBM tumours, additional ROIs were created for the necrotic tumour core (GBM Core), enhancing rim (GBM Rim) and GBM perilesional T2-weighted signal abnormality (GBM Peri).
Biopsy
Biopsies were retrieved from seven of the brain tumour patients. Image processing and analysis was performed on H&E biopsy samples to estimate nuclei volume fraction for comparison with VERDICT estimates of intracellular volume fraction. Nucleus volume fraction was estimated, rather than cellular volume fraction, due to the difficulty in delineating cell boundaries on biopsy samples. In principle, nucleus fractional volume is a valid marker of intracellular volume fraction. The full biopsy image processing pipeline is detailed in the Supplementary Material.
Statistics
For the majority of comparisons in the results, Mann-Whitney-U statistical tests were performed to assess significance. For repeatability measurements of VERDICT parameters in patients, significance was assessed using a Wilcoxon matched-pairs signed rank test. The repeatability coefficient (RC) was also calculated for each parameter, which represents the 95% confidence interval of the difference in the two trials. RC is given by:
where ΔP is the change in parameter value between trials and ̅ is the mean estimate of the VERDICT parameter between trials. For interpretation, the RC provides an indication of the change required to observe a difference above variation.
RESULTS
GL261 mouse glioma response to Temozolomide
GL261 GBM tumours were conspicuous in diffusion weighted images (b = 1000 s/mm 2 )
where the tumour had a lower signal than the rest of the brain ( Figure 1 ). Tumours were also visible on T1-weighted post-gadolinium images, and were characterised by increased signal within the tumour region, compared to normal brain, reflecting raised blood vessel density, blood flow and/or vessel permeability.
Tumour growth increased monotonically with time in both treated and control cohorts ( The vascular volume fraction parameter, fv (Figure 3c ), remained lower than 10% through all timepoints in both cohorts of mice, although at day 6 the parameter was slightly (but significantly) greater in the control group than the TMZ-treated group (p = 0.03).
VERDICT compared with mouse glioma histology and OPT
After the final imaging timepoint (day 9), histology was performed for comparison with VERDICT parameter maps ( Figure 4 ). Coronal histological sections stained with H&E showed a strong accordance with fic and cell radius parameter maps from day 9. In VERDICT maps, tumour regions with a low fic value and low cell radius parameter corresponded well with unstained regions of cell death on histology (Figure 4a ).
Quantitative analysis of H&E stained sections was performed to estimate a two-dimensional histological equivalent of the intracellular volume fraction parameter. A k-means threshold was used to mask the stained tissue (black pixels, Figure 4b) , from which the ratio of stained tissue to unstained regions was calculated. Histological analysis followed the same trend between control and TMZ-treated animals as VERDICT MRI, where the fic parameter was significantly lower in the TMZ-treated group, compared to the control group (Figure 4c , p = 0.02). However, absolute fic parameter values from histology ( Figure 4c , hollow bars) were more than a factor of 2 greater than fic from VERDICT MRI (solid bars).
OPT was also performed after the final imaging time point, on two mouse GBMs labelled with fluorescently-conjugated lectin to estimate a three-dimensional equivalent of the vascular volume fraction parameter, fv. Blood vessel networks were segmented in a control and a TMZ-treated mouse brain ( Figure S2a ). The total volume fraction of the blood vessel network was 0.051 ± 0.002 in the control tumour and 0.048 ± 0.001 in the TMZ-treated tumour, which compared well with fv parameter estimates from VERDICT MRI.
Characterization of human gliomas with VERDICT
Patient demographics, tumour molecular classification, tumour histology and conventional MRI features are shown in Table S3 . The GBMs showed a characteristic tumour mass with an enhancing rim and a non-enhancing necrotic core surrounded by non-enhancing T2- Figure 5g) , indicating that the model fitting for this parameter was unstable in regions of these tumour types. Hence, the mean radius parameters in the astrocytomas and the oligodendrogliomas were considerably higher than for GBMs ( Figure   6e ).
Repeatability of VERDICT parameters
The repeatability of the VERDICT parameters was good for all parameters. No significant differences were observed between repeat trials for any of the fitted parameters (Figure 6f-i) .
The repeatability coefficient was less than 7% for each of the VERDICT parameters, indicating that the fitting was robust and that any variation caused by patient movement was minimised within the image registration pipeline.
VERDICT compared with patient biopsies
Quantitative analysis of H&E stained biopsies was performed to estimate a nuclei volume fraction for comparison with the VERDICT MRI intracellular volume fraction parameter ( Figure S3 ). For all glioma subtypes, the nuclei volume fraction was lower than fic estimated by VERDICT. The oligodendrogliomas had both the largest nuclei volume fraction ( Figure   S3e ) and highest intracellular volume fraction (Figure 5b ). There was a positive correlation between the estimates of nuclei volume fraction and VERDICT fic parameter (Spearman's coefficient, r = 0.71, Figure S3f ), although it did not reach significance (p = 0.09).
DISCUSSION
The aim of this study was to evaluate the use of VERDICT MRI to quantify the microstructure of brain tumours, both in a mouse GBM model and in humans, and to assess its ability to detect acute changes induced by chemotherapy (Temozolomide). We have shown that quantitative microstructural parameters from VERDICT MRI reflected changes induced by chemotherapy in mouse brain tumours, earlier than both ADC and standard measurements of tumour volume using structural MRI, and were consistent with measurements from histological sections from the same brains.
Our measurements of tumour microstructure in the GL261 mouse GBM model provided quantitative values, noninvasively, that were consistent with the known structure of brain tumours. At baseline, mean intracellular volume fraction, fic, was 0.54 ± 0.05, extracellularextravascular volume fraction, fees, was 0.39 ± 0.06, vascular volume fraction, fv, was 0.07 ± 0.02 and cell radius was 10.6 ± 0.6 µm.
An increase in tumour volume was observed over time in both cohorts of mice, but was decelerated in those treated with Temozolomide (TMZ). A significant difference in tumour volume, based on structural MRI, was observed between control and TMZ-treated mice at day 9 of the treatment regimen. In both cohorts of mice, ADC increased as the tumours grew, which was most likely due to the onset of necrosis in both treated and control groups, but was even greater in the TMZ-treated group, probably caused by Temzolomide-induced apoptosis. A significant difference in ADC values was observed between the two cohorts of mice after 6-days of treatment.
VERDICT parameters measured in the pre-clinical study also reflected enhanced cell death in the TMZ-treated group, compared to control tumours. Panagiotaki et al. (2014) reported that the induction of apoptosis produced a significant decrease in colorectal carcinoma intracellular cell volume within 6 hours of treatment with gemcitabine (22) , and was detectable in vivo with VERDICT. In this study, a similar effect was found in brain tumours, although over a longer timescale. Cell radius was the most sensitive of all the VERDICT parameters, producing a significant response to therapy in the TMZ-treated tumours just 3-days after therapy, presumably reflecting a decrease in cell size induced by Temozolomide.
This effect was observed three days earlier than any significant changes in ADC and six days earlier than for volumetric measurements. In the control tumours, the mean cell radius parameter was relatively constant throughout the longitudinal study compared to the TMZtreated tumours, with only a 9.0% decrease in mean radius over the course of the study, compared to a 54.1% decrease in the TMZ-treated mice. Likewise, the intracellular volume fraction decreased more rapidly in the TMZ-treated group compared to the untreated animals, and was significantly lower than controls animals ( Comparison with H&E-stained sections at day-9 post-therapy revealed a strong correspondence between regions of unstained tissue and areas of both low intracellular volume fraction and low cell radius on VERDICT parameter maps, corresponding to regions of greatest necrosis and apoptosis. Quantification of intracellular volume fraction based on H&E slices showed the same trend as VERDICT MRI: cellular density was lower in the TMZtreated animals compared to controls. However, there was a disparity between the absolute values, which were more than a factor of 2 lower according to VERDICT than from histology.
This most likely reflects limitations in the VERDICT model. For example, the model assumes that the cells are impermeable spheres, which is a simplification of the tissue microstructure.
Furthermore, the current VERDICT model does not account for the influence of differences in T2 relaxation times between the compartments (30). However, it could also reflect differences between three-dimensional analysis of cell structure (as is inherent within VERDICT), compared to two-dimensional histological analysis. Based on structural MRI, the tumour phenotype for human GBM was most similar to the GL261 mouse model at day 9. In both mice and patients, a bulk tumour mass was observed containing regions of T2-weighted hyperintensity. However, mouse GBMs enhanced with gadolinium contrast agent across the whole tumour mass, whereas only an area of solid enhancement or rim of enhancement was observed in the GBM patients. There was also no evidence of a peri-tumour region in mice. For ADC and VERDICT parameters, human GBMs were also most similar to GL261 mouse tumours at day 9 compared to the other tumour subtypes. The parameters were actually more comparable with the TMZ-treated cohort of mice rather than the control mice, despite the GBM patients receiving no treatment.
Averaged across the equivalent region in GBM patients (tumour core and rim), fic was 22% compared to 17% in treated mice; fees was 72% compared to 76%; and fv was 6% compared to 7%. The similarity in these values probably reflects that patients with GBMs tend to present late into development of the tumour, whereas the tumours in the untreated mice at Day 9 have yet to progress to this stage. Moreover, it seems that treatment with
Temozolomide has accelerated cell death in the treated cohort to the extent that the volume fractions are comparable with late-stage GBM patients.
VERDICT revealed some interesting sub-regions of heterogeneous tissue microstructure within the peri-tumour zone of the GBMs, which were largely homogenous on the structural images and ADC maps. These regions contained higher fic, lower fees and higher radius parameter values, indicating an increase in restricted diffusion, typical of increased cellular density. It is possible that this simply reflects a greater mix of neuronal and tumour tissue compared to the bulk of the GBM, however, the lack of uniformity across the peri-tumour region indicates pockets of unusual tissue microstructure. Evidence of localised tumour progression within the peri-tumour region is highly desirable for pre-operative surgical planning (33, 34) , therefore further imaging with VERDICT in more GBM patients is required to thoroughly interrogate this finding.
The tissue microstructure in the lower grade astrocytomas and oligodendrogliomas was very different to the GBMs. The VERDICT parameters indicated higher cell density compared to GBMs, especially in the oligodendrogliomas: fic was increased and fees was decreased. The mean radius parameter was considerably higher at 15-16µm, which was caused by many voxels within the astrocytomas and oligodendrogliomas hitting the upper boundary of 20µm.
The implementation of VERDICT used here appears to be less appropriate for modelling these tumour subtypes, possibly because of their diffuse phenotype which infiltrates the normal brain parenchyma, which the VERDICT model was not designed to represent.
Calcification in oligodendrogliomas is common (and has also been observed in astrocytomas (35) ) and known to introduce susceptibility artefacts (36) , which may have also affected the diffusion signal. Alternative biophysical models could be investigated and implemented to better approximate these tumour types (37) .
Comparison of the VERDICT intracellular volume fraction parameter with biopsy data was also conducted. Intracellular volume fraction could not be estimated as the biopsy samples were highly fragmented. Instead, the cell nuclei volume fraction was compared to the VERDICT intracellular volume fraction parameter, which resulted in a positive correlation as expected. A limitation of this comparison was that the biopsy samples were much smaller than the region of interests drawn on the VERDICT intracellular volume fraction parameter maps and that the exact location of the biopsy region was estimated. This likely explains why the correlation did not reach significance, but even with a relatively small number of patients the positive correlation reaffirms that VERDICT reflects the underlying cell density.
There is a growing literature of evidence suggesting that multi-compartment models of the diffusion MRI signal (22, 23, (37) (38) (39) can provide parameters which more accurately reflect the underlying tissue microstructure and that these models provide higher specificity to pathology compared to more traditional single compartment models such as ADC or DTI.
The results of this paper support this consensus. As a potential biomarker of tumour The VERDICT parameters in the patient GBMs appeared to echo the measurements in mouse GBMs, however, the model was less stable when applying the same BallStickSphere to the astrocytomas and oligodendrogliomas. Further studies to optimise VERDICT tissue model for brain tumour subtypes would be invaluable. To this end, ongoing simulations of tumour tissue microenvironments will also be highly important in the optimisation of VERDICT to different tumour types (40) .
To summarise, the current standard for assessing brain tumour therapy response using MRI is to make two-dimensional measurements of tumour size based on structural T1-and T2- 
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SUPPLEMENTARY MATERIALS AND METHODS
Optical Projection Tomography -Preparation, Imaging and Image Processing
Immediately after the final MRI scan, mice were intravenously-injected (via the tail vein) with 100 µg lectin-AlexFluor 647 (Thermo Fisher Scientific, L32451), diluted in sterile saline at neutral pH (100 µl) containing 1 mM CaCl2 in order to fluorescently label blood vessels, which was allowed to circulate for 5 minutes. Mice were then terminally anaesthetised via intraperitoneal injection of 100 mg/kg sodium pentobarbital (Pentoject, Animalcare, York, UK), diluted in 0.1 ml phosphate buffered saline (PBS).
Next, heparin (Wockhardt, Heparin Sodium) diluted in saline was administered by intraperitoneal injection (0.2 ml, with 1000 IU/ml). Mice were perfuse-fixed by opening along the sternum to expose the heart. A small puncture was made in the apex of the heart using micro scissors, and a blunted 25G butterfly cannula was inserted through the left ventricle and into the ascending aorta, where it was secured with a ligature. PBS (30 ml, maintained at 37 °C) was perfused into the heart at 3 ml/min with a perfusion pump (Watson Marlow, 5058). After complete drainage of blood, 40 ml of 4% paraformaldehyde (PFA, VWR chemicals) was perfused.
Intact mouse brains were extracted from the skull and stored for 12 hours in 4% PFA, at 4
°C. Following perfuse-fixation, tumours were rinsed three times in PBS, for 10 minutes each, to remove residual formaldehyde (2). Brain tissue was then optically cleared with BABB (1:2
Benzyl alcohol: Benzyl benzoate), by immersion in methanol for 48 hours followed by immersion in BABB for 48 hours.
Fluorescence within vasculature was visualized with OPT (Bioptonics, MRC Technologies, Edinburgh) using an exposure time of 1600-2000 ms and a rotation step of 0.45 degrees ( Figure S2b ). The final x-y resolution ranged from 4.3 μm to 8 μm, depending on sample size (3). Data were reconstructed using NRecon software (SkyScan, Kontich, Belgium).
Brains were segmented from background by simple thresholding. Tumour tissue was identified by manually drawing a three-dimensional region of interest (ROI) (Amira, FEI, Oregon, US). Background autofluorescence was removed from OPT images by applying a 3-dimensional Gaussian filter of width 25 pixels. Filtered data were subtracted from an unfiltered copy of the data. A Frangi filter was applied to enhance vessel structure. Finally, the data were thresholded to segment vascular structures from background. Data were visualised in three-dimensions using Amira ( Figure S2a ). Blood volume was estimated as the ratio of total vascular volume to tumour ROI volume.
Patient Biopsy Image Processing
Biopsies were retrieved from seven of the brain tumour patients. Image processing was performed on H&E-stained samples to estimate nuclei volume fraction for comparison with VERDICT estimates of intracellular volume fraction. Figure S3 shows the image processing pipeline used to extract nuclei from the images. First, tumour regions within the biopsy slides were sampled and saved as TIFF files at 40x magnification ( Figure S3a ), typically containing 5000 pixels 2 (0.25µm/pixel). Using the Weka Segmentation plug-in (4) for Fiji (NIH, US) (5), two classifiers were trained to represent cell nuclei ( Figure S3b , red) and 'everything else' (green). The same classifier was used for all patient biopsy samples. A binary mask was generated for each biopsy sample ( Figure S3c ), which was then converted to ellipses ( Figure S3d ) using the in-built function within Fiji. The ellipses were constrained to have an area, A > 5um 2 and A < 200um 2 to eliminate noise and any abnormally large ellipses. Nuclei
